Skip to Main Content

Paper Details

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Oncologist
9
2020
BRAF, BRCA1, BRCA1/2, BRCA2, BRCA2 Lys3326Ter, H3F3A, Lys3326Ter (K3226*) nonsense variant, Olaparib, PARP, Patients, Pediatric Glioblastoma, Temozolomide, cancer, cancer predisposition syndrome, girl, glioblastoma, glioma, gliomas, high-grade gliomas, olaparib, parietal-temporal region, patient, patients, pediatric, pediatric glioblastoma, poly (ADP-ribose, poly (ADP-ribose), poly (ADP-ribose) polymerase, seizure activity, temozolomide, tumor
Author NameAffiliation
David E KramWake Forest School of Medicine
David E KramWake Forest Comprehensive Cancer Center, Wake Forest School of Medicine
Vincent A MillerFoundation Medicine, Inc.
Jeffrey S RossFoundation Medicine, Inc.
Jeffrey S RossState University of New York (SUNY) Upstate Medical University
Shakti H RamkissoonWake Forest Comprehensive Cancer Center, Wake Forest School of Medicine
Shakti H RamkissoonWake Forest School of Medicine
Shakti H RamkissoonFoundation Medicine, Inc.
  • 1 - 8

Datasets

Release 1.2